Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | FLT4 | P35916 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5227541 | 0.92 | VCP (0.45) | VCPTNK2KDRIMPDH2JAK2 | |
| SCHEMBL5477651 | 0.92 | VCP (0.44) | VCPKDRIMPDH2JAK2JAK3 | |
| SCHEMBL16349174 | 0.91 | VCP (0.45) | VCPKDRIMPDH2JAK2FLT1 | |
| SCHEMBL5469590 | 0.89 | CCNA2 (0.52) | VCPIMPDH2CCNA2CDK2CCNA1 | |
| SCHEMBL5230752 | 0.89 | VCP (0.43) | VCPKDRIMPDH2FLT1FLT4 | |
| SCHEMBL5475253 | 0.89 | VCP (0.50) | VCPKDRIMPDH2JAK2FLT1 | |
| SCHEMBL5235804 | 0.88 | VCP (0.49) | VCPKDRIMPDH2JAK2FLT1 | |
| SCHEMBL5475439 | 0.87 | VCP (0.60) | VCPKDRIMPDH2JAK2JAK3 | |
| SCHEMBL5477719 | 0.87 | VCP (0.46) | VCPKDRIMPDH2JAK2JAK3 | |
| SCHEMBL16349061 | 0.82 | VCP (0.43) | VCPKDRIMPDH2FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-20070142437-A1 | CHEMICAL COMPOUNDS | BROWN MATTHEW L | 2007-06-21 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189712-B2 | 1,3-Oxazole compounds for the treatment of cancer | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-13 | — | — | US | disclosed |
| US-20050288515-A1 | Chemical compounds | SMITHLINE BEECHAM CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142437-A1 | CHEMICAL COMPOUNDS | CDK4, CDK2, CDK3 | VCP 3873/4885TNK2 200/4885KDR 33/4885 |
| US-20050288515-A1 | Chemical compounds | CDK4, CDK2, CDK3 | VCP 3873/4885TNK2 200/4885KDR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.